EGFR antagonists in cancer treatment

Article Abstract:

Functional activation of growth factors and receptors of the epidermal growth factor receptor (EGFR) family are responsible for human epithelial cancers and so they were targeted for cancer therapy. The EGFR family includes 4 related proteins and 10 different ligands, and two classes of EGFR antagonists in clinical use are anti-EGFR monoclonal antibodies and small molecule EGFR tyrosine kinase inhibitors.

HEALTH SERVICES, Cancer Therapy, Ambulatory Health Care Services, Care and treatment, Methods, Usage, Cancer, Cancer treatment, Monoclonal antibodies, Epithelial tumors, Epithelial tumours

---

Will kinase inhibitors have a dark side?

Article Abstract:

Preclinical observations of kinase inhibitors are raising concern as though the inhibition of protein kinase B should thwart local tumor growth, promoting invasion and metastasis in certain settings. Although the observations are intimidating, the problems can be researched using tools of modern genomics in clinical trials using tissues for making appropriate measurements.

New England States, Clinical trials, Genetic aspects, Protein kinases, New England, Genetic research

---

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors

Article Abstract:

Glioblastomas (EGFRvIII) and phosphatase and tensin homologue deleted in chromosome 10 (PTEN) at the gene and protein levels in glioblastomas from patients before treatment with epidermal growth factor receptor (EGFR) kinase inhibitors are analyzed. Coexpression of EGFRvIII and PTEN by glioblastoma cells is associated with responsiveness to EGFR kinase inhibitors.

Health aspects, Glioblastoma multiforme

Similar abstracts:

• Abstracts: Evaluation of new treatments in radiation oncology: Are they better than standard treatments? Somatic acquisition and signaling of TGFBR1*6A in cancer
• Abstracts: Clinical implications of cyclo-oxygenase-2 inhibitors for acute dental pain management: benefits and risks. part 2
• Abstracts: Massive congenital intracranial teratoma with skull rupture at delivery
• Abstracts: Modulating autoimmunity: Pick your P13 kinase. TCR affinity and negative regulation limit autoimmunity. Blockade of P13Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis
• Abstracts: Diabetic retinopathy mechanism probed. Moderators of treatment outcomes: Clinical ,Research and policy importance

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.